A strength of the study was that implementation of the PHQ-4 in LVS organizations was explored from different perspectives by including all relevant stakeholders (i.e. clients, health care providers administering the PHQ-4, and managers of the LVS organizations). With respect to clients, we included a heterogeneous sample, with respect to age, gender, severity of VI, and history of psychological complaints, to give a good representation of the diversity and different perspectives on (potential) clients of LVS organizations. This heterogeneous sample has provided a variety of perspectives, all relevant for the implementation of the PHQ-4. Moreover, the CFIR was used as a theoretical framework to develop interview guidelines and to analyze the qualitative results. During analysis, the CFIR provided constructs to link barriers and facilitators emerging from each substudy and enabled us to integrate the results of all three substudies. A limitation of the study is that those who participate in research regarding depression and anxiety might have a strong opinion on the importance of implementing the PHQ-4. For example, health care providers who already have a focus on mental health might have been more likely to participate in this study, might be more positive about implementing the PHQ-4, and might identify fewer barriers. Therefore, it is important to keep track of potential barriers during and after implementation and tackle these barriers accordingly. As a second limitation, uncertainty remains about how adequately health care providers administered the PHQ-4, because it is unclear if health care providers completely followed the guidelines during administration. Due to the COVID-19 pandemic, fewer intakes were conducted at the LVS organizations. As a result, experiences with the PHQ-4 were mainly retrieved at one LVS organization, which administered the PHQ-4 to ambulatory clients during regular appointments. It remains unclear whether small-scale implementation within the other LVS organizations and during the intake would have resulted in similar outcomes. In addition, results suggest that administering the PHQ-4 in clients with deaf blindness might be more difficult, but concrete recommendations to improve administration are lacking. There are also doubts about administration to clients with cognitive impairment or psychiatric comorbidity, but recommendations for these groups are lacking as well.